Evidence map›Paper›PMID 41612887›Full record

ArticleEmerging microbes & infections2026

TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection.

Lianne Presley, Jimena Pérez-Vargas, Anaïs Saintigny, Iván Villanueva, Michelle Ho, Jessica Fone, Lara Brinsden, Nidhi Kaushik, Syan Olver, Connor A H Thompson and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lianne PresleyDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Jimena Pérez-VargasDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Anaïs SaintignyDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Iván VillanuevaDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Michelle HoDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Jessica FoneDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Lara BrinsdenDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Nidhi KaushikVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
Syan OlverVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
Connor A H ThompsonDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Diana Bautista-SánchezDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Siobhan EnnisFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Mike ChenFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Matthew McCallumDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Jack T BrownDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Sára FerkováDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada.
Brian HetrickVirongy Biosciences, Inc., Manassas, VA, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Richard LeducDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada.
Masahiro NiikuraFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Pierre-Luc BoudreaultDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada.
Bryce WarnerVaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
François JeanDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Human TMPRSS2 is a type II transmembrane serine protease and an essential host factor for SARS-CoV-2 and influenza A virus (IAV H1N1) infections. It facilitates the cleavage of viral surface glycoproteins, which are required for membrane fusion. This importance makes it an attractive target for host-directed antiviral therapies. We previously identified N-0385 and N-0920 as nanomolar TMPRSS2 inhibitors and demonstrated their antiviral potency against several SARS-CoV-2 variants. Here, we screened another twelve N-0385/N-0920 analogs with improved pharmacokinetics. Compounds

Indexed as

Antiviral AgentsInfluenza A Virus, H1N1 SubtypeOrthomyxoviridae InfectionsSARS-CoV-2Serine EndopeptidasesAnimalsCell LineCOVID-19 Drug TreatmentDibenzothiepinsDogsFemaleHost-Directed TherapyHumansInfluenza, HumanMiceMorpholinesAntiviral AgentsbaloxavirDibenzothiepinsMorpholinesPyridonesSerine EndopeptidasesTMPRSS2 protein, humanTriazinesbroad-spectrum antiviral drugsentry inhibitorshost-directed-antiviralsInfluenza A virusinhibitorsSARS-CoV-2TMPRSS2

Identifiers

PMID41612887
PMCPMC12862872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.